Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study

J Radiat Res. 2024 Jan 19;65(1):63-70. doi: 10.1093/jrr/rrad080.

Abstract

The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.

Keywords: 3D conformal radiotherapy; dose fractionation; glottic carcinoma; head and neck; squamous cell carcinoma; time to treatment.

MeSH terms

  • Carcinoma, Squamous Cell*
  • Head and Neck Neoplasms*
  • Humans
  • Laryngeal Neoplasms* / pathology
  • Laryngeal Neoplasms* / radiotherapy
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck / pathology